SBEV
SPLASH BEVERAGE GROUP, INC.Company Intelligence Hub
Filing history, signal momentum, and bull/bear evolution
Chronological Filing Evolution (Click to filter / toggle)
Thesis (Bull Case Evolution)
Splash Beverage Group is attempting a high-stakes pivot from a distressed beverage shell to a regulated cannabinoid wellness platform.…
Antithesis (Bear Case / Structural Risks)
The financial reality presented in the latest filing depicts a company in a precarious state, characterized by a massive stockholder deficit of $16.2 million and a total liability load of nearly $17 million.…
Read the full bull/bear analysis
You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every SBEV filing.
Synthesis (Verdict & Resolution)
The Q1 2026 filing reveals a company at a binary crossroads. On one side is a strategic evolution into the cannabinoid sector that could provide a legitimate operating base and resolve systemic balance sheet issues. On the other is a terminal decline marked by near-zero revenues and a mountain of convertible debt and preferred obligations that threaten to overwhelm the entity. The immediate focus for investors is the window between now and January 29, 2027, the deadline to regain NYSE compliance. The success of the Medterra acquisition is not just a growth story but a survival requirement. Until Splash can demonstrate a closed transaction and a funded path to extinguish its senior debt, the stock remains a speculative bet on a reverse-merger turnaround against a backdrop of extreme financial fragility.
Core Takeaway
The company is transitioning from a failed beverage model to a cannabinoid wellness platform, but it must raise $10M and close the Medterra deal to avoid being delisted from the NYSE American exchange.
Investor Lens
The trade-off is between the potential for a massive valuation rerating via the cannabinoid pivot versus the high probability of total loss via delisting and bankruptcy.
Watch Next
The May 29, 2026 deadline for the NYSE compliance plan and the execution of the Medterra merger agreement.
Signal Momentum Chart
Quarterly net bull/bear signal ratio. Click nodes to select a quarter.
Signal Timeline
Filing History
The Q1 2026 filing reveals a company at a binary crossroads. On one side is a strategic evolution into the cannabinoid sector that could provide a legitimate operating base and resolve systemic balance sheet issues. On the other is a terminal decline marked by near-zero revenues and a mountain of convertible debt and preferred obligations that threaten to overwhelm the entity. The immediate focus for investors is the window between now and January 29, 2027, the deadline to regain NYSE compliance. The success of the Medterra acquisition is not just a growth story but a survival requirement. Until Splash can demonstrate a closed transaction and a funded path to extinguish its senior debt, the stock remains a speculative bet on a reverse-merger turnaround against a backdrop of extreme financial fragility.
Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.